BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) was the target of a significant increase in short interest in the ...

Fintel reports that on March 19, 2025, Rodman & Renshaw initiated coverage of BioXcel Therapeutics (NasdaqCM:BTAI) with a Buy ...

Artificial Intelligence (AI) and Machine Learning (ML) play a pivotal role in precision oncology, analyzing vast datasets, ...

Rodman & Renshaw initiated coverage of BioXcel Therapeutics (BTAI) with a Buy rating and $65 price target The firm sees e blockbuster ...

Another company involved in using AI to repurpose failed drugs – as well as drugs that have already been approved – is ...

BioXcel Therapeutics, Inc. announced it has raised $14 million in equity financing, providing the company with approximately $35 million in cash to support its pivotal Phase 3 SERENITY At-Home trial.

We recently compiled a list of the 10 Micro-, Small-Cap Firms Were Last Week's Top Performers. In this article, we are going to take a look at where BioXcel Therapeutics, Inc. (NASDAQ:BTAI) stands ...

In this article, we are going to take a look at where BioXcel Therapeutics, Inc. (NASDAQ:BTAI) stands against the other stocks. Micro- and small-cap companies dominated the stock market last week ...

A sublingual film for acute agitation in schizophrenia and bipolar disorder from BioXcel has blockbuster potential that could pose a threat to an inhaled rival from Galen, according to analysts.